News Headlines Article

Breast cancer drug, key to Nektar growth plans, fails clinical trial
San Francisco Business Times

An experimental breast cancer drug from Nektar Therapeutics Inc. — a linchpin of the company’s future growth — failed a late-stage clinical trial, the company said Tuesday. The San Francisco-based drug developer’s stock (NASDAQ: NKTR) was down 16.5 percent, or $2.33 per share to $11.80 , in after-hours trading. The 852-patient trial of the drug, called NKTR-102, focused on the sickest of breast cancer patients: those whose cancer had spread to other parts of their body and who had since been through three other drug therapies.